Replies to post #33071 on Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

There a 4 share raising catalysts by year end...


1) ORR of 70% in ALK+ at ESMO

2) ORR of 30%+ in T790m at World Lung

3) Early EPIC full enrollment triggering earlier mid-2014 readout

4) Data from MD Anderson at ASH demonstrating Pona superiority in 1st and/or 2nd line.

5) wild card...any positive trial data from one of the six non-CML/ALL trials underway with Pona.